SCHEMBL6431437

SCHEMBL6431437

Oc1ccc(C=NNc2nc3nonc3nc2Nc2cccc(Cl)c2)c(O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.50
KMT2A Q03164 11/20 0.50
NPC1 O15118 4/20 0.50
DDX3X O00571 2/20 0.49
GAA P10253 11/20 0.48
MAPT P10636 10/20 0.48
KDM4E B2RXH2 6/20 0.48
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
HPGD P15428 4/20 0.48
LMNA P02545 3/20 0.48
PKM P14618 1/20 0.48
TDP1 Q9NUW8 5/20 0.47
HTT P42858 4/20 0.47
RAB9A P51151 4/20 0.47
POLB P06746 4/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MAPK1 P28482 1/20 0.47
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470009 0.90 DDX3X (0.55) MEN1KMT2ANPC1DDX3XGAA
SCHEMBL6436116 0.90 FADS1 (0.44) MEN1KMT2ANPC1DDX3XGAA
SCHEMBL6436122 0.90 FADS1 (0.44) MEN1KMT2ANPC1DDX3XGAA
SCHEMBL6414918 0.89 DDX3X (0.63) MEN1KMT2ANPC1DDX3XGAA
SCHEMBL6418357 0.88 MAPT (0.47) MEN1KMT2ANPC1DDX3XGAA
SCHEMBL6416491 0.87 MEN1 (0.49) MEN1KMT2ANPC1DDX3XGAA
SCHEMBL6418252 0.87 RRM1 (0.49) MEN1KMT2ANPC1DDX3XGAA
SCHEMBL6440416 0.86 MEN1 (0.47) MEN1KMT2ANPC1DDX3XGAA
SCHEMBL6431153 0.86 MAPT (0.47) MEN1KMT2ANPC1GAAMAPT
SCHEMBL6417232 0.82 DDX3X (0.49) MEN1KMT2ANPC1DDX3XGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MEN1 4392/4885KMT2A 3640/4885NPC1 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.